natgillin/translations-raw huggingface dataset:
In such cases, the starting dose should be 50 mg every other day for patients aged 2 years and older with body weight less than 14 kg and 75 mg every other day for those with body weight 14 kg to less than 25 kg (see sections 4.2 and 5.2).
U takvim slučajevima, početna doza treba biti 50 mg svaki drugi dan u bolesnika u dobi od 2 i više godina i tjelesne težine manje od 14 kg, a 75 mg svaki drugi dan u onih tjelesne težine između 14 kg i manje od 25 kg (vidjeti dijelove 4.2 i 5.2).
In such cases, the starting dose should be as above recommended, but administered every other day.
U takvim slučajevima, početna doza treba biti kako je preporučeno gore, ali primijenjena svaki drugi dan.
In such cases, the Western Blot method is negative.
U takvim slučajevima rezultati metodom Western Blot su negativni.
In such cases, the Western blot method is negative.
U takvim slučajevima tehnika Western Blot daje negativne rezultate.
In such cases, thyroid function should be investigated in order to identify a possible thyroid impairment linked to mitotane treatment.
U takvim slučajevima treba ispitati rad štitne žlijezde kako bi se utvrdilo moguće oštećenje štitne žlijezde povezano s liječenjem mitotanom.
In such cases, you should be aware that the side effects may be more intense.
U takvim slučajevima, morate znati da bi se nuspojave mogle pojačati.
In such circumstance, the discontinuation of dalbavancin and the use of supportive measures together with the administration of specific treatment for Clostridium difficile should be considered.
U takvim okolnostima, potrebno je razmotriti prestanak primjene dalbavancina i primjenu potpornih mjera zajedno s primjenom specifičnog liječenja za Clostridium difficile.
In such circumstances Neulasta should be discontinued at the discretion of the physician and the appropriate treatment given (see section 4.8).
U takvim slučajevima prema procjeni liječnika primjenu Neulaste treba prekinuti i primijeniti odgovarajuće liječenje (vidjeti dio 4.8).
In such circumstances, the discontinuation of therapy with ceftolozane/tazobactam and the use of supportive measures together with the administration of specific treatment for Clostridium difficile should be considered.
U takvim okolnostima potrebno je razmotriti prekid terapije ceftolozanom/tazobaktamom i primjenu potpornih mjera zajedno sa specifičnim liječenjem za Clostridium difficile.
In such instances, instructions for antibody testing should be followed.
U takvim slučajevima treba postupati po uputama za testiranje antitijela.
In such patients haematological parameters should be carefully monitored.
Kod tih bolesnika nužno je pažljivo praćenje hematoloških parametara.
In such patients it is advisable to introduce entacapone treatment as a separate treatment (entacapone tablets) and adjust the levodopa dose if necessary, before switching to Levodopa/Carbidopa/Entacapone Orion.
Kod takvih bolesnika je preporučljivo uvesti entakapon kao odvojeni lijek (entakapon tablete) i po potrebi prilagoditi dozu levodope, prije prelaska na Levodopa/Carbidopa/Entacapone Orion.
In such patients, cardiac function should be monitored with particular care during the period of initial dose adjustment.
U takvih se bolesnika, s naročitom pažnjom mora pratiti srčana funkcija tijekom razdoblja početne prilagodbe doze.
In such patients, interruption or discontinuation of treatment must be considered (see section 4.8).
U tih pacijenata mora se razmotriti privremeni ili trajni prekid terapije (vidjeti dio 4.8).
In such patients, treatment with Gilenya should be considered only if the anticipated benefits outweigh the potential risks.
U takvih bolesnika liječenje Gilenyjom treba uzeti u obzir samo ako očekivana korist premašuje potencijalni rizik.
In such situations, your surgeon will be informed and might have to select an alternative treatment for you.
U takvim će situacijama Vaš kirurg o tome biti obaviješten i možda će morati za Vas odabrati neko drugo liječenje.
In summary, dexmedetomidine, by decreasing central noradrenergic and serotonergic neurotransmission, is effective in alleviating canine acute anxiety and fear associated with noise.
Ukratko, smanjenjem centralne noradrenergične i serotonergične neurotransmisije deksmedetomidin učinkovito u pasa ublažava akutnu anksioznost i strah povezane s bukom.
In summary, everolimus is a highly effective therapy for this neuronal model of TSC, with benefit apparently attributable to effects on mTORC1 and Akt signalling and, consequently, cell size and myelination.
U sažetku, everolimus se u ovome neuronskom modelu KTS-a pokazao visokoučinkovitom terapijom čija se dobrobiti po svemu sudeći može pripisati utjecaju na mTORC1 i Akt signalne putove, a time posredno i na veličinu stanica i mijelinizaciju.
In summary, the combination of erlotinib with proton pump inhibitors should be avoided.
Treba izbjegavati kombinaciju erlotiniba i inhibitora protonske pumpe.
In summary, the limited size of the overall paediatric exposure is insufficient to guide safe and effective dosing of IONSYS in patients younger than 18 years of age.
Ukratko, ograničen opseg cjelokupne pedijatrijske izloženosti nedovoljan je da bi se mogao koristiti kao vodič za sigurno i učinkovito doziranje sustava IONSYS u bolesnika mlađih od 18 godina.
In summary, these studies suggest that low dose radioiodine plus thyrotropin alpha is an effective treatment (with reduced radiation exposure) and Thyrogen was non-inferior to thyroid hormone withdrawal for pre-therapeutic stimulation in combination with radioiodine for post-surgical ablation of thyroid remnant tissue.
Sažeto, ova ispitivanja pokazuju da kombinacija niske doze radioaktivnog joda i tireotropina alfa predstavlja djelotvornu terapiju (sa smanjenom izloženošću zračenju) i da Thyrogen nije bio inferioran prekidu terapije tireoidnim hormonom za predterapijsku stimulaciju u kombinaciji s radioaktivnim jodom u svrhu poslijeoperacijske ablacije ostatnog tkiva štitnjače.
In surgery studies in which parecoxib was administered pre-operatively, no evidence of pharmacodynamic interaction was observed in patients receiving parecoxib and the inhalation anaesthetic agents nitrous oxide and isoflurane (see section 5.1).
U kirurškim ispitivanjima u kojima se parekoksib primjenjivao prije operacije nije zamijećen nikakav dokaz farmakodinamičke interakcije u bolesnika koji su primali parekoksib i inhalacijske anestetike dušikov oksid i izofluran (vidjeti dio 5.1).
In systemic juvenile idiopathic arthritis, RoActemra given by infusion has been compared with placebo in one main study involving 112 children who had inadequate responses to NSAID and systemic corticosteroid treatment.
U slučaju sistemskog juvenilnog idiopatskog artritisa, lijek RoActemra primijenjen infuzijom uspoređen je s placebom u jednom glavnom ispitivanju kojim je obuhvaćeno 112 djece koja nisu primjereno odgovorila na NSAID i sistemsko liječenje kortikosteroidima.
In systemic juvenile idiopathic arthritis, RoActemra is given as a 1-hour infusion once every two weeks at a dose of 8 mg per kilogram body weight in children weighing 30 kg or more, or 12 mg per kilogram body weight in children weighing less than 30 kg.
U slučaju sistemskog juvenilnog idiopatskog artritisa RoActemra se primjenjuje kao infuzija u trajanju od jednog sata svaka dva tjedna u dozi od 8 mg po kilogramu tjelesne težine u djece koja teže 30 kg ili više, odnosno 12 mg po kilogramu tjelesne težine u djece koja teže manje od 30 kg.
In systemic sclerosis with digital ulcers, Tracleer was more effective at reducing the development of new digital ulcers than placebo.
U slučaju sistemske skleroze s digitalnim ulceracijama, Tracleer je bio djelotvorniji u smanjivanju razvoja novih digitalnih ulceracija u odnosu na placebo.
In systemic sclerosis with digital ulcers, two studies have compared Tracleer film-coated tablets with placebo in a total of 312 adults.
U slučaju sistemske skleroze s digitalnim ulceracijama, dva su ispitivanja usporedila filmom obložene tablete lijeka Tracleer s placebom u ukupno 312 odrasle osobe.
In T-ALL the abnormal cells are mainly in the blood and bone marrow, and in T-LBL they are mainly in the lymphatic system (lymph nodes or thymus gland).
U slučaju T-ALL, abnormalne stanice se nalaze uglavnom u krvi i leđnoj moždini, a u slučaju T-LBL nalaze se uglavnom u limfatičnom sustavu (limfnim čvorovima i timusnoj žljezdi).
In table 1 a complete list of known adverse reactions is presented.
U Tablici 1 prikazan je cjeloviti popis svih poznatih nuspojava.
In table 1 a complete list of known adverse reactions is presented.
U Tablici 1 prikazan je popis svih poznatih nuspojava.
In table 2 below all adverse reactions, which occurred at an incidence greater than placebo and in more than one patient, are listed by class and frequency (very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).
U Tablici 2. ispod, sve nuspojave koje su se javile s većom incidencijom u odnosu na placebo i u više od jednog bolesnika popisane prema organskim sustavima i učestalosti pojavljivanja (vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
In table 2 below all adverse reactions, which occurred at an incidence greater than placebo and in more than one patient, are listed by class and frequency: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not
U Tablici 2 u nastavku, sve nuspojave koje su se javile s većom incidencijom u odnosu na placebo i u više od jednog bolesnika popisane su prema organskim sustavima i učestalosti pojavljivanja: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i
In Table 4 the efficacy results of patients undergoing percutaneous coronary intervention (PCI) are presented.
U tablici 4 prikazani su rezultati djelotvornosti u bolesnika koji su podvrgnuti perkutanom koronarnom zahvatu.
In target animal safety studies, administration of the maximum recommended injection volume (5 ml) very commonly caused slight swellings at the injection site that were not painful on palpation.
U ispitivanju neškodljivosti kod određenih vrsta životinja, primjena najveće preporučene doze ( 5 ml) vrlo često uzrokuje blago oticanje na mjestu aplikacije koje nije bolno.
In TAUSSIG, long-term use of Repatha demonstrated a sustained treatment effect as evidenced by reduction of LDL-C of approximately 20% to 30% in patients with homozygous familial hypercholesterolaemia not on apheresis and approximately 15% to 25% in patients with homozygous familial hypercholesterolaemia on apheresis (table 7).
U ispitivanju TAUSSIG, dugoročna primjena lijeka Repatha pokazala je održani učinak liječenja, kao što je dokazano smanjenjem vrijednosti LDL-C-a od oko 20% do 30% u bolesnika s homozigotnom obiteljskom hiperkolesterolemijom koji nisu bili na aferezi, te oko 15% do 25% u bolesnika s homozigotnom obiteljskom hiperkolesterolemija na aferezi (Tablica 7).
In Taxespira 20 mg/1 ml, 80 mg/4 ml, 120 mg/6 ml, 140 mg/7 ml and 160 mg/8 ml vials the concentration of docetaxel is 20 mg/ ml.
U bočicama Taxespira 20 mg/1 ml, 80 mg/4 ml, 120 mg/6 ml, 140 mg/7 ml i 160 mg/8 ml koncentracija docetaksela je 20 mg/ml.
In Taxespira 20 mg/1 ml, 80 mg/4 ml, 120 mg/6 ml, 140 mg/7 ml and 160 mg/8 ml vials the concentration of docetaxel is 20 mg/ml.
U bočicama Taxespira 20 mg/1 ml, 80 mg/4 ml, 120 mg/6, 140 mg/7 ml i 160 mg/8 ml koncentracija docetaksela je 20 mg/ml.
In TAXOTERE 20 mg /1 ml vial the concentration of docetaxel is 20 mg/ml.
U bočici TAXOTERE 20 mg/l ml, koncentracija docetaksela iznosi 20 mg/ml.
In TAXOTERE 20 mg/1 ml vial the concentration of docetaxel is 20 mg/ml.
U bočici TAXOTERE 20 mg/1 ml, koncentracija docetaksela iznosi 20 mg/ml.
In TAXOTERE 80 mg /4 ml vial the concentration of docetaxel is 20 mg/ml.
U bočici TAXOTERE 80 mg/4 ml, koncentracija docetaksela iznosi 20 mg/ml.
In terms of reproductive development, growth and neurological development there were no propranolol-related effects or toxicologically significant findings at 40 mg/kg/day, correlating to safety margins of 1.2 in females and 2.9 in males, based on mean propranolol exposures on PND 21.
U pogledu reproduktivnog razvoja, rasta i neurološkog razvoja nije bilo učinaka povezanih s propranololom ili toksikološki značajnih nalaza pri 40 mg/kg/dnevno s obzirom na granice sigurnosti od 1,2 kod žena i 2,9 kod muškaraca, na temelju srednje vrijednosti izloženosti propranolola na PND 21.
In terms of safety, Enzepi’s side effects are comparable to other marketed products.
U pogledu sigurnosti nuspojave lijeka Enzepi usporedive su s drugim lijekovima koji su u prometu.
In thalassaemia patients there is an association between liver fibrosis and iron overload and/or hepatitis C. Special care must be taken to ensure that iron chelation in patients with hepatitis C is optimal.
U bolesnika s talasemijom postoji povezanost između fibroze jetre i preopterećenja željezom i/ili hepatitisa C. Mora se posebno paziti da kelacija željeza u bolesnika s hepatitisom C bude optimalna.
In that case carry on with the next dose as normal.
U tom slučaju se sljedeća doza uzima normalno.
In that case hCG should be withheld and pregnancy should be avoided to prevent multiple gestations.
U tom slučaju se ne smije primijeniti hCG i mora se izbjeći trudnoća kako bi se spriječila višeplodna trudnoća.
In that case infusion sets with minimal priming space should be used (i.e.
U tom je slučaju potrebno primjenjivati komplete za infuziju s minimalnim prostorom za ubrizgavanje (tj.
In that case the needle should be attached without screwing.
U tom slučaju iglu treba pričvrstiti bez navijanja.
In that case, an initial oral tacrolimus dose of 2 to 4 mg per day was used in combination with mycophenolate mofetil and corticosteroids or in combination with sirolimus and corticosteroids.
U tom se slučaju davala početna peroralna doza takrolimusa od 2 do 4 mg na dan u kombinaciji s mikofenolat mofetilom i kortikosteroidima ili u kombinaciji sa sirolimusom i kortikosteroidima.
In that case, intravenous voriconazole administration is recommended.
U takvim se slučajevima preporučuje intravenska primjena vorikonazola.
In that case, the first dose (V1) of vaccine can be given concurrently with the appropriate prophylactic dose of Tetanus-Serum from Intervet at a separate injection site, using separate syringes and needles.
U tom slučaju, prva doza (V1) cjepiva može se dati istovremeno s prikladnom profilaktičnom dozom Tetanus – Serum (Intervet) na različitim mjestima uboda, koristeći zasebne šprice i igle.
In that study ctDNA derived from serum, not plasma was used for EGFR mutation analysis using the EGFR Mutation Test Kit (DxS) (N= 86).
U tom se ispitivanju za analizu mutacije EGFR-a koristila ctDNK iz seruma, a ne iz plazme, a provedena je uz pomoć kompleta testnih reagensa EGFR Mutation Test Kit (DxS) (N= 86).
In the 1- to 24 mg/kg cohorts, peak serum concentrations (Cmax) after the first dose increased in approximate proportion to dose and volume of distribution was consistent with initial distribution into the plasma compartment.
U kohortama koje su primale doze od 1 do 24 mg/kg, vršne serumske koncentracije (Cmax) nakon prve doze povećavale su se približno proporcionalno dozi, a volumen distribucije bio je u skladu s početnom distribucijom u plazmatski odjeljak.
In the 11-18 year old population of the pivotal study, V59P13, the immunogenicity of a single dose of Menveo one month post vaccination is compared with the ACWY-D.
U populaciji staroj od 11 do 18 godina u pivotalnom ispitivanju V59P13, imunogenost pojedinačne doze cjepiva Menveo mjesec dana nakon cijepljenja uspoređena je s ACWY-D.
In the 12 week acute phase of three clinical trials of duloxetine in patients with diabetic neuropathic pain, small but statistically significant increases in fasting blood glucose were observed in duloxetine- treated patients.
U 12-tjednoj akutnoj fazi triju kliničkih ispitivanja duloksetina u bolesnica s boli kod dijabetičke neuropatije primijećena su mala, ali statistički značajna povećanja glukoze u krvi natašte u bolesnica liječenih duloksetinom.
In the 12 week acute phase of three clinical trials of duloxetine in patients with diabetic neuropathic pain, small but statistically significant increases in fasting blood glucose were observed in duloxetine- treated patients.
U 12-tjednoj akutnoj fazi triju kliničkih ispitivanja duloksetina u bolesnika s boli kod dijabetičke neuropatije primijećena su mala, ali statistički značajna povećanja glukoze u krvi natašte u bolesnika liječenih duloksetinom.
In the 12 week acute phase of three clinical trials of duloxetine in patients with diabetic neuropathic pain, small but statistically significant increases in fasting blood glucose were observed in duloxetine- treated patients.
U 12-tjednoj akutnoj fazi triju kliničkih ispitivanja duloksetina u bolesnika s bolom kod dijabetičke neuropatije primijećena su mala, ali statistički značajna povećanja koncentracije glukoze u krvi natašte u bolesnika koji su uzimali duloksetin.
In the 12 week controlled phase, the rate of all infections in the tocilizumab group was 344.7 per 100 patient years and 287.0 per 100 patient years in the placebo group.
Tijekom 12-tjedne kontrolirane faze ispitivanja, stopa svih infekcija u skupini koja je primala tocilizumab bila je 344,7 na 100 bolesnik-godina, a u skupini koja je primala placebo 287,0 na 100 bolesnik-godina.
In the 12 week controlled phase, the rate of serious infections in the tocilizumab group was 11.5 per 100 patient years.
Tijekom 12-tjedne kontrolirane faze ispitivanja stopa ozbiljnih infekcija u skupini koja je primala tocilizumab bila je 11,5 na 100 bolesnik-godina.
In the 12-14 months age group who received 2 doses of Nimenrix given 2 months apart, the first and second doses were associated with similar local and systemic reactogenicity.
U dobnoj skupini ispitanika od 12 - 14 mjeseci koja je primila 2 doze Nimenrixa dane u razmaku od 2 mjeseca, prva i druga doza povezane su sa sličnom lokalnom i sistemskom reaktogenošću.
In the 12-14 months age group who received 2 doses of Nimenrix given 2 months apart, the first and second doses were associated with similar local and systemic reactogenicity.
U dobnoj skupini ispitanika od 12 - 14 mjeseci koja primi 2 doze Nimenrixa dane u razmaku od 2 mjeseca, prva i druga doza povezane su sa sličnom lokalnom i sistemskom reaktogenošću.
In the 12-23 months and 2-5 years age groups, the most frequently reported general adverse reactions after vaccination were irritability (44.0% and 9.2% respectively), drowsiness (34.1% and 10.8% respectively), loss of appetite (26.6% and 8.2% respectively), and fever (17.1% and 8.1% respectively).
U dobnoj skupini ispitanika od 12-23 mjeseca i 2-5 godina najčešće prijavljene opće nuspojave nakon cijepljenja bile su razdražljivost (44,0% odnosno 9,2%), omamljenost (34,1% odnosno 10,8%), gubitak apetita (26,6% odnosno 8,2%) i vrućica (17,1% odnosno 8,1%).
In the 12-week study, Incruse statistically significantly reduced the use of rescue medication with salbutamol compared with placebo (on average a reduction of 0.7 puffs per day over Weeks 1-12, p=0.025) and demonstrated a higher percentage of days when no rescue medication was needed (on average 46.3%) compared with placebo (on average 35.2%; no formal statistical analysis was performed on this endpoint).
U 12-tjednom ispitivanju je primjena lijeka Incruse statistički značajno smanjila uporabu salbutamola kao lijeka za hitno ublažavanje simptoma (engl. rescue medication) u usporedbi s placebom (prosječno smanjenje za 0,7 udisaja na dan u razdoblju od 1. do 12. tjedna, p=0,025) te povećala postotak dana kada uporaba lijekova za hitno ublažavanje simptoma nije bila potrebna (u prosjeku 46,3%) u usporedbi s placebom (u prosjeku 35,2%; nije provedena formalna statistička analiza za tu mjeru ishoda).
In the 120-week C208 trial where SIRTURO was administered for 24 weeks in combination with a background regimen, more deaths occurred in the SIRTURO treatment group than in the placebo group (see section 4.8).
U 120-tjednom ispitivanju C208 u kojem je SIRTURO primijenjen tijekom 24 tjedna u kombinaciji s osnovnim liječenjem, više smrtnih slučajeva dogodilo se u skupini liječenoj lijekom SIRTURO u odnosu na placebo skupinu (vidjeti dio 4.8).
In the 13 week study, female bone marrow and lymphoid changes are reported at the high dose with a weak incidence.
U tom ispitivanju, u trajanju od 13 tjedana, u ženki su kod visokih doza zabilježene promjene u koštanoj srži i limfoidne promjene, ali s niskom incidencijom.
In the 16 patients with MCD treated with 11 mg/kg every 3 weeks, overall tumour response rate by independent review was 43.8% with 6.3% complete response.
U 16 bolesnika s MCD-om koji su liječeni s 11 mg/kg svaka 3 tjedna, ukupna stopa tumorskog odgovora nezavisnom procjenom bila je 43,8% s 6,3% potpunog odgovora.
In the 2 active controlled a DVT/PE treatment trials, RE-COVER and RE-COVER II, a total of 2,553 patients were included in the safety analysis for dabigatran etexilate.
U analizi sigurnosti za dabigatraneteksilat u dvama aktivnim kontroliranim ispitivanjima liječenja DVT/PE-a, naziva RE-COVER i RE-COVER II, ukupno je bilo uključeno 2 553 bolesnika.
In the 2 active controlled DVT/PE treatment trials, RE-COVER and RE-COVER II, a total of 2,553 patients were included in the safety analysis for dabigatran etexilate.
U analizi sigurnosti za dabigatraneteksilat u dvama aktivnim kontroliranim ispitivanjima liječenja DVT/PE-a, naziva RE-COVER i RE-COVER II, ukupno je bilo uključeno 2 553 bolesnika.
In the 2 clinical studies that included an active comparator (UNCOVER-2 and UNCOVER-3), the rate of serious adverse events was 1.9 % for both etanercept and for Taltz, and the rate of discontinuation due to adverse events was 1.2 % for etanercept and 2.0 % for Taltz.
U dvama kliničkim ispitivanjima koja su uključivala aktivan usporedni lijek (UNCOVER-2 i UNCOVER-3), stopa ozbiljnih štetnih događaja iznosila je 1,9% i uz etanercept i uz Taltz, dok je stopa prekida liječenja zbog štetnih događaja iznosila 1,2% uz etanercept i 2,0% uz Taltz.
In the 2-year active- controlled study where patients were treated with either etanercept alone, methotrexate alone or etanercept in combination with methotrexate, the rates of serious infections were similar among the treatment groups.
U dvogodišnjem aktivno kontroliranom ispitivanju u kojem su bolesnici liječeni samo etanerceptom, samo metotreksatom ili etanerceptom u kombinaciji s metotreksatom, stope ozbiljnih infekcija bile su slične za sve liječene skupine.
In the 2-year rat carcinogenicity study administration of imatinib at 15, 30 and 60 mg/kg/day resulted in a statistically significant reduction in the longevity of males at 60 mg/kg/day and females at
U 2-godišnjoj studiji karcinogenosti u štakora primjena imatiniba od 15, 30 i 60 mg/kg/dan rezultirala je statistički značajnim smanjenjem dužine života mužjaka uz 60 mg/kg/dan i ženki uz
In the 2-year rat carcinogenicity study administration of imatinib at 15, 30 and 60 mg/kg/day resulted in a statistically significant reduction in the longevity of males at 60 mg/kg/day and females at ≥ 30 mg/kg/day.
U 2-godišnjoj studiji karcinogenosti u štakora primjena imatiniba od 15, 30 i 60 mg/kg/dan rezultirala je statistički značajnim smanjenjem dužine života mužjaka uz 60 mg/kg/dan i ženki uz ≥30 mg/kg/dan.
In the 20 integrated placebo-controlled studies, elevations in liver aminotransferases  3 times the upper limit of normal (ULN) were observed in 11.2% of the bosentan-treated patients as compared to 2.4% of the placebo-treated patients.
U 20 integriranih placebom kontroliranih studija povišenje jetrenih aminotransferaza ≥ 3 puta u odnosu na gornju granicu normale (GGN) primijećeno je u 11,2% bolesnika koji su dobivali bosentan u odnosu na 2,4% bolesnika koji su dobivali placebo.